Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 2:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 278 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Organ Transplantation
Interventions
everolimus (RAD)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
68
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Chronic Heart Failure
Interventions
MTP-101-C encapsulated Microbiota, Vancomycin, Neomycin
Biological · Drug
Lead sponsor
Melana Yuzefpolskaya, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Heart Transplantation
Interventions
Belatacept, Tacrolimus, Mycophenolate Mofetil, Corticosteroid
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Heart Transplantation
Interventions
Enteric-coated Mycophenolate Sodium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
162 participants
Timeline
Started 2002
U.S. locations
3
States / cities
Los Angeles, California • Minneapolis, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Heart Failure, Transplant; Failure, Heart
Interventions
Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
Device
Lead sponsor
XVIVO Perfusion
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Heart Transplantation
Interventions
Bradykinin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Cardiac Allograft Vasculopathy
Interventions
Perflutren Lipid Microsphere, RTMPE
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced May 22, 2026, 2:44 AM EDT
Completed Phase 4 Interventional Results available
Conditions
Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity, Neutropenia
Interventions
Letermovir
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Graft Rejection, Heart Diseases
Interventions
Endomyocardial biopsy, AlloMap Molecular Testing
Procedure
Lead sponsor
XDx
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2010 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Heart Transplant Failure, Determination of Death, Outcomes Research, Death
Interventions
Heart Transplantation
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Heart Transplantation, Allograft Arteriopathy
Interventions
Latent class mixed modeling
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Cardiac Allograft Vasculopathy
Interventions
Thymoglobulin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced May 22, 2026, 2:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
Conditions
Heart Transplantation
Interventions
Magnetic Resonance Spectroscopy, Ex vivo heart biopsy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Ischemia Reperfusion Injury, Heart Transplantation
Interventions
Anti-Thymocyte Globulin, Normal Saline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced May 22, 2026, 2:44 AM EDT
Completed Not applicable Interventional Results available
Conditions
Complete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Syndrome
Interventions
Cultured Thymus Tissue
Biological
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced May 22, 2026, 2:44 AM EDT
Terminated No phase listed Observational Results available
Conditions
Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients
Interventions
Induction Therapy, Tacrolimus, Mycophenolate Mofetil, Intraoperative plasma exchange/pheresis, Short-term post-operative plasmapheresis, Immunoglobulins, Intravenous, Prednisone
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced May 22, 2026, 2:44 AM EDT
Conditions
RENAL INSUFFICIENCY, CHRONIC, LIVER FAILURE, ACUTE, HEART DISEASE
Interventions
ProQuad
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
6 Months to 24 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Cardiac Allograft Vasculopathy
Interventions
Macitentan
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Vascular; Change, Dietary Modification, Physical Activity, Health Behavior, Attitude to Health
Interventions
On-Line Diet and Exercise Intervention
Other
Lead sponsor
Stanford University
Other
Eligibility
9 Years to 19 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Cardiac Allograft Vasculopathy
Interventions
Sirolimus
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 2 Interventional
Conditions
Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Hyper-IgM, DiGeorge Syndrome, Chediak-Higashi Syndrome, Common Variable Immune Deficiency, Immune Dysregulatory Disorders, Hemophagocytic Lymphohistiocytosis, IPEX, Autoimmune Lymphoproliferative Syndrome, X-linked Lymphoproliferative Syndrome
Interventions
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Heart Transplant
Interventions
OCS Heart, Static Cold Storage (SCS)
Device · Other
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
San Francisco, California • Tampa, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Chronic Lung Disease, Chronic Obstructive Pulmonary Disease, Acute Lymphoblastic Leukemia, Heart Transplant
Interventions
Physical activity
Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
8 Years to 25 Years
Enrollment
90 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced May 22, 2026, 2:44 AM EDT
Conditions
Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions
Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo
Biological
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced May 22, 2026, 2:44 AM EDT